Eli Lilly and Co. said foreign-exchange pressures weighed on sales in the most recent quarter as the pharmaceutical company continued to suffer the impact of patent expirations on some of its key drugs.
WSJ.com: US Business, Wall Street Journal: Business
Fri, 01/30/2015 - 4:49am
Eli Lilly and Co. said foreign-exchange pressures weighed on sales in the most recent quarter as the pharmaceutical company continued to suffer the impact of patent expirations on some of its key drugs.